Search bioRxiv⌕ Search

bioRxiv · 10.1101/2024.04.04.588122

Ovarian support cell in vitro maturation (OSC-IVM) results in healthy murine live births with no evidence of reprotoxicology in a multigenerational study

Abstract

Study questionDoes application of human stem cell-derived ovarian support cells (OSCs) for in vitro maturation (IVM) have a safe reproductive toxicity profile? Summary answerThe use of OSC-IVM co-culture improves blastocyst formation in a mouse model and results in healthy live births with no evidence of reprotoxicity. What is known alreadyAbbreviated stimulation to obtain immature oocytes combined with a successful IVM offers a promising alternative to traditional in vitro fertilization, reducing hormonal doses and making IVF shorter and safer. Recently, we developed an OSC platform derived from human induced pluripotent stem cells (hiPSCs) that replicate dynamic ovarian function in vitro, enhancing human oocyte maturation and yielding an improved blastocyst formation rate compared to commercial IVM options. However, the reproductive toxicity profile, commonly assessed via murine multigenerational models, for OSC-IVM remains unknown. Study design, size, durationA total of 70 B6/CBA 6-8-week-old stimulated female mice were used in this study to collect immature mouse oocytes (n=2,025) at the germinal vesicle (GV) stage. Half of these oocytes were retrieved denuded (denuded oocytes condition, n= 930), while the remaining oocytes were kept with the cumulus cells (COCs condition, n= 1,095) to simulate the two possible dispositions of oocytes during clinical practice. Oocytes from each condition, denuded oocytes and COCs, were randomly assigned to either commercially available traditional IVM media (MediCult-IVMTM, Origio) group (control group) or the same traditional IVM media supplemented with human OSCs (FertiloTM, Gameto Inc.) to form the OSC-IVM group (test group). Participants/materials, setting, methodsOocytes from each condition, denuded oocytes and COCs, were subjected to in vitro culture for 18-20 hours. After IVM, metaphase II (M2) oocytes were inseminated by intracytoplasmic sperm injection (ICSI) and cultured to assess blastocyst formation in vitro. Embryos that reached the blastocyst stage on day five were vitrified using Kitazatos protocol in preparation for embryo transfers. A group of M2 oocytes and blastocyst embryos were employed for quality analyses by immunofluorescence. Vitrified blastocysts were warmed and transferred to pseudopregnant females (4-5 embryos per uterine horn), evaluating the F1 offspring. Pup characteristics were tracked, including weight, length, sex ratio, and physiology. Weekly monitoring assessed mouse behavior and development. At reproductive age, select F1 mice were outbred to wildtype mice to produce the F2 generation, analyzing live births, sex ratio, morphology, and behavior across groups. Moreover, hormonal and organ histological analyses were performed in F1 mice to further explore the overall health of the progeny. Main results and the role of chanceIn contrast to findings in humans, in mice OSC-IVM generally led to a decreased maturation rate compared to Traditional-IVM (68.6% {+/-} 14.1% versus 80.9% {+/-} 5.9%, p=0.0101). Subsequent embryo culture yielded significantly different fertilization rates between the four groups (p=0.0055). Specifically, OSC-IVM with COCs significantly differed from Traditional-IVM with denuded oocytes (89.5 {+/-} 10.5 versus 96.5 {+/-} 4.8, p=0.0098). There were no differences in the cleavage rates (p=0.7547). However, there was a significant distinction in the blastocyst formation (p=0.0068), wherein OSC-IVM with COCs showed a greater formation rate compared to Traditional-IVM for both denuded oocytes and COCs (56.1% {+/-} 19.2% versus 41.5% {+/-} 15.9% and 38.0% {+/-} 16.2%; p=0.0408, and p=0.0063). Spindle morphology analysis demonstrated normal spindle morphology in denuded oocytes and COCs under both Traditional-IVM and OSC-IVM. Moreover, embryo analysis showed no significant difference in inner cell mass count (p=0.1550). Following embryo transfers, analysis of live births showed no significant distinctions between groups regarding delivery, sex ratio, pup length, developmental and behavioral abnormalities, hormonal values or histopathological anomalies in the F1 generation. Evaluation of the F2 generation also showed no significant differences in live births, sex ratio, or developmental/behavioral abnormalities between groups, further validating the absence of long-term implications and transgenerational effects derived from OSC-IVM culture. Limitations, reasons for cautionAlthough this study was conducted in compliance with European Medicines Agency (EMA) ICH E6 (R2) Good clinical practice scientific guidelines to demonstrate the OSC safety, human clinical studies evaluating in vivo and live birth outcomes are necessary to corroborate the findings of this study. Wider implications of the findingsThis study provides evidence of the safety of using the OSC-IVM system, as evidenced by the lack of adverse effects on in vitro embryo development post OSC-IVM and on the health and fertility of offspring across successive generations in vivo. Trial registration numberN/A

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Marchante, M., Barrachina, F., Mestres, E., Acacio, M., Potts, K. S., Piechota, S., Paulsen, B., Noblett, A. D., Figueroa, A. B., Costa-Borges, N., Kramme, C. C.. 2024-04-06. Ovarian support cell in vitro maturation (OSC-IVM) results in healthy murine live births with no evidence of reprotoxicology in a multigenerational study. https://doi.org/10.1101/2024.04.04.588122

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Denaturation-sensitive BRET probes enable intracellular thermal shift measurements across diverse protein targets and biomolecular complexes

Thermal shift assays have revolutionized drug discovery, but can be limited in sensitivity and scalability. Combining the unique attributes of differential scanning fluorimetry (DSF) and cellular thermal shift (CETSA), we report the methodological framework for the bioluminescence resonance energy transfer shift assay (BRETSA). BRETSA utilizes denaturation sensitive BRET probes, in combination with luciferase-tagged target proteins, to track and longitudinally record thermal shift in living cells. Denaturation profiles were successfully measured for over 500 globular proteins, spanning 24 target families in diverse cellular compartments. Among these, target engagement was confirmed for over 200 proteins; including validated drug targets as well as understudied members of the kinase subfamily. Leveraging orthosteric, allosteric, and covalent ligands in potency studies, this method offers improved sensitivity and scalability compared to other thermal shift methods. We extend the utility of BRETSA to interrogate target engagement at biomolecular complexes and query cooperative binding for molecular glues and emerging tricomplex drug modalities.

pharmacology and toxicology↗

Peptide Sequence Determines the Efficacy of Single-Dose AAV-Vectorized GLP-1R Agonists in Diet-Induced Obese Mice

Background: Glucagon-like peptide-1 receptor (GLP-1R) agonists such as semaglutide produce substantial weight loss and glycemic improvement, but their long-term efficacy depends on sustained adherence to chronic dosing. Adeno-associated virus (AAV) gene therapy could, in principle, provide durable GLP-1R agonist (GLP-1RA) exposure from a single administration, but the degree of peptide engineering required for a vectorized GLP-1RA transgene to be efficacious in vivo is unknown. Methods: We generated four self-complementary AAV (scAAV) constructs encoding: native human GLP-1(7-36) (GLP-1), a DPP-IV-resistant Gly8-GLP-1(7-36) variant (Gly8), Exendin-4 (Ex4), or an Exendin-4 human IgG4 Fc fusion protein (Ex4-Fc). All four constructs were validated to secrete functional GLP-1R agonists in vitro using a conditioned-media potency assay. Subsequently, these constructs were packaged into PHP.eB capsids and administered as a single intravenous dose (5x1012 vg/kg) to diet-induced obese (DIO) mice alongside a vehicle control. Body weight, body composition, food intake, fasting plasma insulin, and oral glucose tolerance were assessed over a 3-week period. At the end of the study, tissues were harvested for assessments of plasma/liver lipids, tissue transgene transcript and peptide levels. Results: HEK293 cells transfected with the four AAV constructs all secreted active peptides/proteins as assessed by a cell-based GLP-1R activation assay, although the effective concentration of the GLP-1 constructs in the media spanned nearly four orders of magnitude 72 hours after transfection. In diet-induced obese (DIO) mice, Ex4 and Ex4-Fc vectors, but not GLP-1 or Gly8 vectors, produced significant reductions in body weight of up to 22.6% of starting body weight out to 21 days after a single dose. In addition, reductions in food intake, fat mass, and fasting insulin relative to vehicle were also observed for Ex4 and Ex4-Fc. Furthermore, Ex4-Fc improved oral glucose tolerance while reducing plasma cholesterol and liver triglycerides relative to vehicle. Although transcript levels did not differ appreciably among the four constructs in either brain or liver, measurable peptide product in plasma and brain lysate tracked the rank order of the in vitro supernatant screen, with GLP-1 and Gly8 groups indistinguishable from endogenous background. Conclusions: PHP.eB scAAV Ex4 and Ex4-Fc showed robust efficacy on multiple metabolic endpoints including weight loss and glucose tolerance. In contrast, vectorized GLP-1 and Gly8 showed no in vivo efficacy despite comparable levels of viral transcript in the brain and the liver. Vectorized GLP-1 and Gly8 also performed poorly compared to exendin-4-based constructs in vitro, suggesting that conditioned-media potency screening is a valid early filter for construct selection in vectorized-peptide AAV development. Engineering peptides to improve translation and secretion efficiency, in addition to circulating plasma stability, could further optimize vectorized GLP-1RA therapeutics.

pharmacology and toxicology↗

Preclinical Evaluation of a Novel BOC-Modified Triazoloacridinone (TRA-01AR) in Combination with 5-Fluorouracil in Colorectal Cancer

5-Fluorouracil (5-FU) remains a cornerstone of colorectal cancer (CRC) therapy, yet its clinical efficacy is limited by resistance, systemic toxicity, and unfavorable pharmacokinetics. Strategies that enhance tumor sensitivity while maintaining tolerability are therefore of considerable interest. Here, we evaluated 5-FU in combination with two triazoloacridinones, C-1305 and a novel BOC-modified derivative, TRA-01AR, using integrated cellular, transcriptomic, bioenergetic, and in vivo approaches. Both compounds induced cytotoxic effects across cancer cell models and produced overlapping but distinct transcriptional responses, primarily affecting DNA replication and cell cycle pathways. Bioenergetic profiling revealed a shift toward oxidative phosphorylation accompanied by reduced glycolysis, indicating modulation of cellular metabolism relevant to chemotherapy response. Interestingly, TRA-01AR exhibited delayed cytotoxicity relative to C-1305, although the underlying mechanism remains to be defined. In vivo, the combination of 5-FU with C-1305 significantly reduced tumor weight in HT-29 xenografts, whereas 5-FU combined with TRA-01AR did not result in a statistically significant reduction compared to 5-FU alone. TRA-01AR was associated with a more favorable systemic profile and increased intratumoral blood flow compared with C-1305. Collectively, these findings indicate that triazoloacridinones modulate transcriptional and metabolic programs relevant to the 5-FU response. While C-1305 demonstrated greater antitumor activity under the tested conditions, TRA-01AR exhibited distinct biological effects, including improved tolerability and vascular modulation. Further studies are required to clarify TRA-01AR's mechanism of action and assess its potential relevance in CRC-specific therapies.

pharmacology and toxicology↗